Considering most of the patients with hypercholesterolemia are in the older age group with multiple comorbidities, including renal dysfunction, PCSK9 inhibitors like evolocumab and alirocumab would be helpful in such cases, as monoclonal antibodies are relatively safe in renal dysfunction. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.